REG-Shire plc: Notice of Results

* Reuters is not responsible for the content in this press release.

Mon Apr 20, 2009 11:49am EDT 

First quarter 2009 results date notification - April 30, 2009

April 20, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, will announce first quarter 2009 earnings on
Thursday April 30, 2009.

Results press release will be   12:00 BST / 07:00 EDT                          
issued at:                                                                     
                                                                               
Investor conference call time:  14:30 BST / 09:30 EDT                          

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial
Officer will host the investor and analyst conference call at 14:30 BST/9:30
EDT.

The details of the conference call are as follows:

UK dial in:            0808 100 5150                                           
                                                                               
US dial in:            1 866 804 8688 or 1 718 354 1175                        
                                                                               
International dial in: +44 (0) 1296 480 100                                    
                                                                               
Password/Conf ID:      228 831                                                 
                                                                               
Live Webcast:          http://www.shire.com/shire/InvestorRelations/index.jsp? 
                       tn=2                                                    

Replay:

A replay of the presentation will be available for two weeks by phone and by
webcast for one year. Details can be found on our Investor Relations website 
http://www.shire.com/shire/InvestorRelations/index.jsp?tn=2 .

For further information please contact:

Investor Relations  Souheil Salah (Rest of the World)        +44 1256 894 160  
                                                                               
                    Ricki Greenwood (North America)          +1 484 595 8517   

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder (ADHD), human
genetic therapies (HGT) and gastrointestinal (GI) diseases as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: 
www.shire.com.

                                                                              2

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX


Press Release                                     
                                                  
www.shire.com                                     



END
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.